Insider · CIK 0001973872
Anna Nijdam
Files at PHVS (Pharvaris N.V.). First filing May 26, 2026, latest Jun 8, 2026.
In brief
Anna Nijdam files SEC Form 4 as officer at PHVS (Pharvaris N.V.). Since May 26, 2026, Anna Nijdam has reported 0 open-market buys worth $0 and 2 open-market sells worth $307k, the latest filed on Jun 8, 2026.
A track record needs three past buys with six months of prices behind them; Anna Nijdam has 0, so none is measured yet.
The newest scored trade: sold $82k of PHVS on Jun 4, 2026, filed Jun 8, 2026, scored 39 (weak). In the last 12 months: 0 buys worth $0 and 2 sells worth $307k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PHVS: Pharvaris N.V.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 39Weak | Pharvaris N.V. | $82k 2,670 shares | -5% | +97% from low-4% from high | |
| 33Weak | Pharvaris N.V. | $225k 7,330 shares | -14% | +98% from low-7% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 4, 2026 | PHVS PHARVARIS N.V. | 2,670 0.00% of outstanding | $82k | Jun 4, 2026 | $225k |
| May 22, 2026 | PHVS PHARVARIS N.V. | 5,501 0.01% of outstanding | $169k | May 22, 2026 | $56k |
| May 21, 2026 | PHVS PHARVARIS N.V. | 1,829 0.00% of outstanding | $56k | May 21, 2026 | none |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | PHVS Pharvaris N.V. | SOpen-market sale Common Stock | -2,670 | $30.87 | $82k | 46,275 | Jun 8, 2026 |
| May 21, 2026 | PHVS Pharvaris N.V. | MOption exercise Common Stock | +1,829 | $20.00 | $37k | 50,774 | May 26, 2026 |
| May 21, 2026 | PHVS Pharvaris N.V. | SOpen-market sale Common Stock | -1,829 | $30.60 | $56k | 48,945 | May 26, 2026 |
| May 22, 2026 | PHVS Pharvaris N.V. | MOption exercise Common Stock | +5,501 | $20.00 | $110k | 54,446 | May 26, 2026 |
| May 22, 2026 | PHVS Pharvaris N.V. | SOpen-market sale Common Stock | -5,501 | $30.74 | $169k | 48,945 | May 26, 2026 |
| May 21, 2026 | PHVS Pharvaris N.V. | MOption exercise Stock Option (Right to Buy)derivative | -1,829 | $0.00 | $0 | 28,171 | May 26, 2026 |
| May 22, 2026 | PHVS Pharvaris N.V. | MOption exercise Stock Option (Right to Buy)derivative | -5,501 | $0.00 | $0 | 22,670 | May 26, 2026 |
| Apr 11, 2026 | PHVS Pharvaris N.V. | FTax withholding Common Stock | -548 | $26.63 | $15k | 48,940 | Apr 14, 2026 |
| Apr 6, 2026 | PHVS Pharvaris N.V. | FTax withholding Common Stock | -1,167 | $28.56 | $33k | 49,488 | Apr 8, 2026 |
| Apr 1, 2026 | PHVS Pharvaris N.V. | FTax withholding Common Stock | -1,164 | $28.25 | $33k | 50,655 | Apr 3, 2026 |
Questions about Anna Nijdam
Answered from the filings on this page, as of the latest one.
Is Anna Nijdam buying or selling?
In the last 12 months Anna Nijdam reported 0 open-market buys worth $0 and 2 open-market sells worth $307k on SEC Form 4; the latest was sold $82k of PHVS on Jun 4, 2026. Grants, option exercises and tax withholding are not counted.
How did Anna Nijdam's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Anna Nijdam has 0.
Where does Anna Nijdam file Form 4?
Anna Nijdam has filed Form 4 at PHVS (Pharvaris N.V.) as Principal Accounting Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.